The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
Francis Levi
No relevant relationships to disclose
Abdoulaye KarabouƩ
No relevant relationships to disclose
Raphaƫl Saffroy
No relevant relationships to disclose
Elodie Peyric
No relevant relationships to disclose
Michel Ducreux
No relevant relationships to disclose
Denis Michel Smith
No relevant relationships to disclose
Mohamed Hebbar
No relevant relationships to disclose
Pasquale F. Innominato
No relevant relationships to disclose
Simon Pernot
No relevant relationships to disclose
Carlos Carvalho
No relevant relationships to disclose
Rosine Guimbaud
No relevant relationships to disclose
C. N. J. Focan
No relevant relationships to disclose
Mohamed Bouchahda
No relevant relationships to disclose
Rene Adam
No relevant relationships to disclose
Marie-Christine Etienne-Grimaldi
No relevant relationships to disclose
Gerard A. Milano
No relevant relationships to disclose
Antoinette Lemoine
No relevant relationships to disclose